Bank of New York Mellon Corp Decreases Stock Holdings in DaVita Inc. (NYSE:DVA)

Bank of New York Mellon Corp decreased its holdings in shares of DaVita Inc. (NYSE:DVA) by 8.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 381,794 shares of the company’s stock after selling 35,664 shares during the period. Bank of New York Mellon Corp owned about 0.47% of DaVita worth $57,097,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its position in shares of DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock valued at $99,846,000 after buying an additional 92,014 shares in the last quarter. KBC Group NV lifted its holdings in DaVita by 0.8% in the 4th quarter. KBC Group NV now owns 316,155 shares of the company’s stock valued at $47,281,000 after purchasing an additional 2,636 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in DaVita by 23.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company’s stock valued at $47,874,000 after purchasing an additional 56,389 shares in the last quarter. Nordea Investment Management AB lifted its holdings in DaVita by 4.9% in the 4th quarter. Nordea Investment Management AB now owns 264,535 shares of the company’s stock valued at $39,712,000 after purchasing an additional 12,339 shares in the last quarter. Finally, FMR LLC lifted its holdings in DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock valued at $29,082,000 after purchasing an additional 154,061 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Down 1.0 %

NYSE DVA opened at $141.70 on Wednesday. DaVita Inc. has a 52 week low of $125.64 and a 52 week high of $179.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The business’s fifty day simple moving average is $160.19 and its 200-day simple moving average is $158.12. The firm has a market cap of $11.34 billion, a PE ratio of 13.19, a P/E/G ratio of 1.07 and a beta of 0.94.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, equities analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DVA. Sanford C. Bernstein set a $184.00 price objective on DaVita in a report on Friday, February 21st. Barclays raised their price objective on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. Finally, Cowen restated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, DaVita has a consensus rating of “Hold” and an average price target of $166.33.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.